Vomiting News and Research

RSS

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

Hyperoxygenation postsurgery benefits in doubt

Supplementation with 80% fraction of inspired oxygen during surgery does not reduce patients’ risk for surgical site infections, research shows.

19 Jul 2012

Ferring Pharmaceuticals receives FDA approval for new colon-cleansing drug

On July 16, the U.S. Food and Drug Administration approved Prepopik (sodium picosulfate, magnesium oxide and citric acid) to help cleanse the colon in adults preparing for colonoscopy.

17 Jul 2012

UCB’s Neupro now available in U.S. pharmacies

UCB announced today that Neupro (Rotigotine Transdermal System) is now available in U.S. pharmacies. Neupro was approved by the U.S Food and Drug Administration in April to treat the signs and symptoms of early and advanced stage idiopathic Parkinson's disease and moderate-to-severe primary Restless Legs Syndrome.

16 Jul 2012

Migraine involves multiple symptoms that vary widely among sufferers

Almost everyone suffers from headache pain occasionally, but for 36 million Americans, intense, debilitating headaches accompanied by other neurological symptoms — also known as migraine syndrome — are a source of physical misery that can have a devastating effect on their quality of life. It is estimated that the medical expenses and loss of productivity caused by migraine costs Americans $20 billion annually.

14 Jul 2012

Pressure Point develops 72 hour low-cost dermal device to effectively reduce PONV

Pressure Point Inc. has developed an effective 72 hour low-cost, FDA Market Cleared dermal device, which uses an advanced acupressure approach for longer-acting prophylactic results in reducing the occurrences of postoperative nausea and vomiting.

12 Jul 2012

Radiotherapy redundant in low-risk Hodgkin lymphoma treatment

Children with low-risk Hodgkin lymphoma who respond well to chemotherapy may not require additional radiotherapy, suggest study results.

10 Jul 2012

Cook Medical receives FDA clearance for Evolution Colonic Controlled-Release Stent

The U.S. Food and Drug Administration (FDA) has granted Cook Medical 510(k) clearance for the Evolution Colonic Controlled-Release Stent, Cook announced today.

9 Jul 2012

Conference highlights utility of zebrafish for human disorder studies

Zebrafish, popular as aquarium fish, now have an important place in research labs as a model organism for studying human diseases.

8 Jul 2012

Children at increased risk for heat-related illness

Extreme heat continues to plague the nation with many areas seeing record temperatures. Though everyone needs to take precautions when it comes to dangerous heat, it's especially important to watch your kids. Children are at a greater risk than adults of sustaining a heat injury.

4 Jul 2012

Signs that a child is seriously ill: Interview with Professor Middleton

There are several signs that indicate that a child is seriously ill. These can be spotted by parents, teachers and carers as well as by me or any other doctor or nurse.

4 Jul 2012

Acute pancreatitis: An interview with Viktor Oskarsson

Acute pancreatitis is an inflammatory disease of the pancreas. The most common symptom is acute abdominal pain, which is often accompanied with nausea and vomiting.

4 Jul 2012

Safety tips to prevent heatstroke during hot weather

People across the country are experiencing sweltering weather with temperatures and the heat index reaching well into the 100-degree range. While many will take refuge in air-conditioned homes or at a local lake or pool, it's important to remember that the heat can be much more than bothersome. It can put your health at risk and even prove life threatening.

3 Jul 2012

Savient's KRYSTEXXA improves HRQOL and physical function in patients with RCG

Savient Pharmaceuticals, Inc. announced a new publication showing that adult patients with refractory chronic gout (RCG) treated bi-weekly with KRYSTEXXA- (pegloticase) experienced statistically significant and clinically meaningful improvements in health-related quality of life (HRQOL), pain and physical function.

3 Jul 2012

USPTO issues notice of allowance to Avanir for NUEDEXTA

Avanir Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed a new patent that covers Avanir's product NUEDEXTA, further expanding the intellectual property portfolio for the company's lead commercial asset.

2 Jul 2012

CIHR and CH.I.L.D. create Canadian Children Inflammatory Bowel Disease Network

Dr. Grace McCarthy, Chairman of the Board of The Foundation for Children with Intestinal and Liver Disorders (CH.I.L.D), today announced an important new partnership with the Canadian Institutes of Health Research (CIHR) to fund the creation of the Canadian Children Inflammatory Bowel Disease Network: A Joint Partnership of CIHR and the CH.I.L.D. Foundation.

30 Jun 2012

A.P. Pharma announces additional data from APF530 Phase 3 study on CINV

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced additional data from the Company's Phase 3 study of APF530 for the prevention of chemotherapy-induced nausea and vomiting (CINV).

29 Jun 2012

LUMC oncologist presents survival data for brentuximab vedotin at 17th EHA Congress

A new cancer drug with remarkably few side effects is dramatically improving survival in Hodgkin lymphoma patients who fail other treatments and are nearly out of options.

28 Jun 2012

FDA approves Baxter's GAMMAGARD LIQUID for multifocal motor neuropathy

Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] as a treatment for multifocal motor neuropathy (MMN). This is the first immunoglobulin treatment approved for MMN patients in the United States, and it was approved for use with MMN patients in Europe in 2011.

From Baxter International Inc. 25 Jun 2012

Genentech's Perjeta helps people with HER2-positive metastatic breast cancer live longer

Genentech, a member of the Roche Group, announced today that people with HER2-positive metastatic breast cancer (mBC) lived significantly longer (overall survival) when treated with the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy, compared to Herceptin and docetaxel chemotherapy alone in the Phase III CLEOPATRA study.

23 Jun 2012